Cosmo Pharmaceuticals: Adjusted Net Profit of $31 Million for 2025, Up 7.9% YoY

DoNews March 24 – ReCor Medical Technology (01696.HK) announced that for the fiscal year ending December 31, 2025, it achieved revenue of $365 million, a 5% increase year-over-year; gross profit was $215 million, a 0.7% decrease; profit attributable to the parent company’s owners was $19.016 million, a 24.3% decrease; adjusted net profit was $31 million, a 7.9% increase. Basic earnings per share for the year were 4.06 cents, with a proposed final dividend of HKD 0.095 per share (tax included).

During the reporting period, the group’s gross profit decreased by 0.7% to $215 million. The gross profit margin declined from 62.1% in 2024 to 58.9% during the reporting period. This decrease was mainly due to changes in regional and product mix as well as newly implemented import tariffs.

Financial Overview

Revenue was $365.3 million, a 4.7% increase compared to 2024.

Injectable filler business revenue was $28.0 million, a 185.6% increase year-over-year.

International markets (excluding North America) revenue grew by 20.1% compared to 2024.

Asia-Pacific revenue was $147.4 million, a 26.9% increase from 2024, accounting for 40.4% of total revenue, making it the largest regional contributor. Revenue from Europe, the Middle East, and Africa was $56.4 million and $36.4 million, respectively, representing increases of 11.7% and 5.3% compared to 2024. North America revenue was $111.0 million, a 19.2% decrease from 2024.

Gross profit margin was 58.9%, down from 62.1% in 2024. The decline was mainly due to regional revenue structure adjustments, product mix changes, and the impact of newly implemented import tariffs.

Net profit was $25.0 million, down 13.1% from $28.8 million in 2024. Net profit margin was 6.8%, compared to 8.2% in 2024. Adjusted net profit was $31 million, a 7.9% increase from $28.7 million in 2024. The adjusted net profit margin was 8.5%, up from 8.2% in 2024.